teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 36 Projects Releases Packages Wiki Activity Actions 866

extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics #1237

Closed
leo wants to merge 2 commits from extract/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics into main
pull from: extract/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics
merge into: teleo:main
Conversation 4 Commits 2 Files changed 6 +4 -4
4 changed files with 4 additions and 4 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files
Showing only changes of commit b7c946cc55 - Show all commits

2
domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
View file

@ -79,7 +79,7 @@ Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF
### Additional Evidence (extend)
*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16*
BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plus manufacturer-funded lifestyle support represents the first major policy attempt to address the chronic-use cost structure. The Medicare GLP-1 Bridge (July 2026) provides immediate price relief while full model architecture is built, indicating urgency around cost containment.

2
domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md
View file

@ -50,7 +50,7 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0
### Additional Evidence (extend)
*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16*
*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16*
Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk.

2
domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md
View file

@ -36,7 +36,7 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k
### Additional Evidence (confirm)
*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16*
*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16*
SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings.

2
domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md
View file

@ -49,7 +49,7 @@ The BALANCE Model moves payment toward genuine risk by adjusting capitated rates
### Additional Evidence (extend)
*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16*
CMS BALANCE Model demonstrates policy recognition of the VBC misalignment by implementing capitation adjustment (paying plans MORE for obesity coverage) plus reinsurance (removing tail risk) rather than expecting prevention incentives to emerge from capitation alone. This is explicit structural redesign around the identified barriers.